

MAR 25 2002

MAR 22 2002

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002, OMB 0551-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number	09/737,687
Filing Date	12/14/00
First Named Inventor	Allen, Darin Arthur
Group Art Unit	1626
Examiner Name	Wright, Sonya N.
Attorney Docket Number	218

Total Number of Pages in This Submission

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Supplemental IDS under 37 CFR Sect. 1.97 & Sect. 1.98
Remarks <input type="text"/>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Axys Pharmaceuticals, Inc. Rekha Bansal (Reg. No. 36,440)
Signature	<i>Rekha Bansal</i>
Date	3/22/02

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 3/22/2002

Typed or printed name	EUGENE NEUBET	Date	3/22/2002
Signature	<i>Eugene Neubet</i>		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to

PATENT
Attorney Docket No: 218

Assistant Commissioner for Patents
Washington, DC 20231

On March 22 2002

Axis Pharmaceuticals, Inc.

By: [Signature]

MAR 22 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Darin Arthur Allen, et al.

Application No.: 09/737,687

Filed: December 14, 2000

For: SALICYLAMIDES AS SERINE
PROTEASE INHIBITORS

Examiner: Sonya N. Wright

Art Unit: 1626

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR § 1.97 AND § 1.98

Assistant Commissioner for Patents
Washington, DC. 20231

Sir:


The references cited on attached form PTO/SB/08A are being called to the attention of the Examiner. These references were cited in the International Preliminary Examination Report (PCT Rule 71.1) in a corresponding PCT application. Enclosed are copies of the Notification of Transmittal of the International Preliminary Examination Report (PCT Rule 71.1) and a copy of the International Preliminary Examination Report (PCT Article 36 and Rule 70) along with copies of the cited references. It is respectfully requested that the cited references be expressly considered during the prosecution of this

application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required because the Supplemental Information Disclosure Statement is being submitted within three months of the mailing of the Notification of Transmittal of the International Preliminary Examination Report (PCT Rule 71.1) and the International Preliminary Examination Report (PCT Article 36 and Rule 70) mailed from the International Preliminary Examining Authority on February 22, 2002. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0848. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Rekha Bansal
Reg. No. 36,440

AXYS PHARMACEUTICALS, INC.
180 Kimball Way
South San Francisco, CA 94080
Tel: 650-829-1000
Fax: 650-866-6651